JO
VYNT

John Overdeck’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

John Overdeck’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-189
Closed -$116K – 3370
2017
Q1 		$116K Buy
+189
New +$67.2K ﹤0.01% 2782

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $169M AUM 12.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $167M AUM 33.45% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DM
Diker Management New York $130M AUM 97.77% 1-Year Est. Return

John Overdeck's VYNT Position: Q2 2017 in Review

John Overdeck sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q2 2017, closing a stake of 189 shares — an estimated $116K sold.

John Overdeck first reported a position in VYNT in Q1 2017 and held it in 1 quarter. The position peaked at $116K in Q1 2017. 28 funds tracked by Wall St. Rank hold VYNT as of Q2 2017.

  • John Overdeck reported no remaining Vyant Bio, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • John Overdeck sold 189 Vyant Bio, Inc. Common Stock shares in Q2 2017, an estimated $116K.
  • John Overdeck first reported a position in Vyant Bio, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • John Overdeck's Vyant Bio, Inc. Common Stock position peaked at $116K in Q1 2017.
  • 28 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q2 2017.

Based on Two Sigma Investments's 13F filing for Q2 2017, filed 14 Aug 2017.